Trade Summary

3 days ago, O'Neill Gilmore Neil, serving as CEO at Editas Medicine, Inc. (EDIT), sold 15,380 shares at $2.70 per share, for a total transaction value of $41,542.92. Following this transaction, O'Neill Gilmore Neil now holds 248,313 shares of EDIT.

This sale represents a 5.83% decrease in O'Neill Gilmore Neil's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, June 3, 2026 and publicly disclosed via SEC Form 4 filing on Friday, June 5, 2026 at 4:33 PM ET, 2 days after the trade was made.

Editas Medicine, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.